Summary: Cynomolgus macaques, used in drug metabolism studies due to their evolutionary closeness to humans, are mainly bred in Asian countries, including Cambodia, China, and Indonesia. Cytochromes P450 (P450s) are important drug-metabolizing enzymes, present in the liver and small intestine, major drug metabolizing organs. Previously, our investigation did not find statistically significant differences in hepatic P450 metabolic activities measured in cynomolgus macaques bred in Cambodia (MacfaCAM) and China (MacfaCHN). In the present study, P450 metabolic activity was investigated in the small intestine of MacfaCAM and MacfaCHN, and cynomolgus macaques bred in Indonesia (MacfaIDN) using P450 substrates, including 7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, S-mephenytoin, bufuralol, chlorzoxazone, and testosterone. The results indicated that P450 metabolic activity of the small intestine was not statistically significantly different (<2.0-fold) in MacfaCAM, MacfaCHN, and MacfaIDN. In addition, statistically significant sex differences were not observed (<2.0-fold) in any P450 metabolic activity in MacfaCAM as supported by mRNA expression results. These results suggest that P450 metabolic activity of the small intestine does not significantly differ statistically among MacfaCAM, MacfaCHN, and MacfaIDN.
Introduction
The cynomolgus macaque (Macaca fascicularis) is an important primate species for drug metabolism studies, since this species has molecular and functional properties of important drug-metabolizing enzymes similar to humans, including cytochromes P450 (P450s or CYPs). 1) P450 is a gene family consisting of a large number of drugmetabolizing enzyme genes. In humans, the CYP3A subfamily enzymes are important due to their involvement in the biotransformation of >50% of prescription drugs 2) and their abundant expression in the liver and small intestine. 3, 4) CYP3A enzymes catalyze the metabolism of some orally administered drugs, thus exerting a first-pass effect. 5) In cynomolgus macaques, more than 20 P450s have been identified to date, including CYP1A1, CYP1D1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2C76, CYP2D17, CYP2E1, CYP3A4, and CYP3A5. 1) In this paper, we have designated cynomolgus CYP2C20, CYP2C43, CYP2C75, and CYP3A8 as CYP2C8, CYP2C9, CYP2C19, and CYP3A4, respectively, after consulting with the P450 Nomenclature Committee (http://drnelson.uthsc.edu/ cytochromeP450.html). Similar to humans, CYP3A enzymes predominate the total P450 content of the liver in cynomolgus macaques. 6) Although the content of each P450 in the small intestine has not been reported for cynomolgus macaques, expression of CYP3A4 and CYP3A5 mRNAs is relatively abundant in the small intestine among the 14 P450 mRNAs analyzed. 7) Moreover, first-pass metabolism of CYP3A substrates, including midazolam, fexofenadine, and simvastatin, has been observed in the cynomolgus macaque intestine. 8) Therefore, CYP3A enzymes might also play important roles in first-pass metabolism in the cynomolgus macaque small intestine.
Cynomolgus macaques used for biomedical research are mainly bred in Asian countries, including Cambodia (MacfaCAM), China (MacfaCHN), and Indonesia (MacfaIDN). We previously did not find any statistically significant differences in the activities or mRNA expressions of hepatic P450 enzymes in MacfaCAM and MacfaCHN. 9) However, such studies have not been done in the small intestine. In the present study, P450 metabolic activities were measured in the small intestine (jejunum) of MacfaCAM, MacfaCHN, and MacfaIDN, using nine P450 substrates, 7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, Smephenytoin, bufuralol, chlorzoxazone, and testosterone. Sex differences and inter-animal variations of P450 metabolic activities were also assessed in the jejunum of MacfaCAM. Furthermore, the mRNA expression of the eleven P450s responsible for these metabolic reactions was also measured in the jejunum of males and females (MacfaCAM) by quantitative PCR (qPCR) analysis.
Materials and Methods
Materials: Bufuralol, chlorzoxazone, 7-ethoxyresorufin, and S-mephenytoin were purchased from Sigma-Aldrich (St. Louis, MO). Coumarin, diclofenac, paclitaxel, and testosterone were purchased from Wako Pure Chemical Industries (Osaka, Japan). Bupropion and NADPH-regenerating system solutions were purchased from BD Gentest (Woburn, MA). All other reagents were purchased from Wako Pure Chemical Industries unless otherwise specified.
Tissue samples and preparation of RNA and microsomes: Small intestine (jejunum) samples were collected from 54 cynomolgus macaques (weighing 3-5 kg), including 40 MacfaCAM (3-4 years of age, 20 males, 20 females), 9 MacfaCHN (4-10 years of age, all males), and 5 MacfaIND (3-10 years of age, 4 males, 1 female). Animals were fed a standard animal diet (i.e., Teklad Global Certified 25% Protein Primate Diet, Harlan Sprague-Dawley, Indianapolis, IN), and food was provided ad libitum except during the overnight fasting periods before sampling. The present study was reviewed and approved by the Institutional Animal Care and Use Committee of Shin Nippon Biomedical Laboratories, Ltd. Total RNA was extracted from jejunum samples from 20 MacfaCAM (10 males and 10 females), as previously described. 7) For all animals, microsomes were prepared from jejunum samples as described previously. 10) Microsomal protein concentrations were determined by the Bradford method (Bio-Rad Protein Assay Kit, Bio-Rad, Hercules, CA) using bovine serum albumin as the standard.
Enzyme assays: Metabolic activity of cynomolgus P450s was measured using 7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, S-mephenytoin, bufuralol, chlorzoxazone, and testosterone as substrates, according to the previous method. 10) Briefly, a typical incubation mixture (0.5 mL) contained jejunum microsomes (0.025, 0.1, or 0.25 mg protein/mL), an NADPHgenerating system (0.25 mM NADP + , 2.5 mM glucose 6-phosphate, and 0.25 unit/mL glucose 6-phosphate dehydrogenase), and substrate (20 µM bufuralol, 160 µM bupropion, 50 µM chlorzoxazone, 3 µM coumarin, 20 µM diclofenac, 0.8 µM 7-ethoxyresorufin, 60 µM S-mephenytoin, 15 µM paclitaxel, or 100 µM testosterone). Reactions were incubated at 37°C for 5, 10, or 20 min and terminated by addition of 0.25 mL of ice-cold acetonitrile. Metabolites in supernatants obtained by centrifugation at 7,500 © g (10 min) or 10,000 © g (15 min) were analyzed by liquid chromatography coupled with tandem mass spectrometry or radio high-performance liquid chromatography, as described previously. 10) qPCR analysis: Expression of CYP1A1, CYP1D1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2C76, CYP2D17, CYP2E1, CYP3A4, CYP3A5, and pregnane X receptor (PXR) mRNA was measured by real-time reverse transcription (RT)-PCR as described previously. 7, 11, 12) The relative expression levels were determined by normalizing the raw data to the 18S ribosomal RNA level, based on three independent amplifications. To estimate a correlation between P450 mRNA levels, linear regression analysis was performed using Microsoft Excel (Microsoft, Redmond, WA). Statistical significance was determined for metabolic activities and mRNA expressions of P450s using a two-tailed unpaired Student's t-test. Values were considered statistically significant if p was <0.05.
Results and Discussion
Metabolic activities of cynomolgus P450s were measured in 40 MacfaCAM (20 males, 20 females), 9 MacfaCHN (all males), and 5 MacfaIND (4 males, 1 female) using P450 substrates. The reactions analyzed included 7-ethoxyresorufin O-deethylation for CYP1A/ 1D; coumarin 7-hydroxylation for CYP2A; bupropion hydroxylation and testosterone 16¢-hydroxylation for CYP2B; diclofenac 4A-hydroxylation, paclitaxel 6¡-hydroxylation, and S-mephenytoin 4A-hydroxylation for CYP2C; bufuralol 1A-hydroxylation for CYP2D; chlorzoxazone 6-hydroxylation for CYP2E1; and testosterone 6¢-hydroxylation for CYP3A. All reactions were detected in the small intestine except for coumarin 7-hydroxylation and testosterone 16¡-hydroxylation ( Table 1) . S-Mephenytoin 4A-hydroxylation was not detected in 4 animals. Comparison of male samples revealed that the P450 metabolic activities analyzed were not statistically significantly different (<2.0-fold) among MacfaCAM, MacfaCHN, and MacfaIND (Supplemental Fig. 1 ). The largest differences were observed between MacfaCHN and MacfaIND testosterone 2¡-hydroxylation (1.5-fold). These results indicated the similarities in the P450 metabolic activities among MacfaCAM, MacfaCHN, and MacfaIND.
The rate of testosterone 6¢-hydroxylation in the small intestine ( Table 1 ) was comparable with that in the liver, which we reported previously. 9) Since cynomolgus CYP3A is the most abundant P450 protein in the liver, 6) cynomolgus CYP3A might also be abundant in the small intestine. Indeed, our immuno-quantification of P450s revealed that CYP3A was the most abundant P450 in the cynomolgus small intestine, among the P450s analyzed, using antibodies raised against nine P450s of the CYP1-3 families (Uehara and Uno, unpublished data). In humans, CYP3A is also the most abundant P450 in the small intestine.
3) These results suggest that CYP3A enzymes play important roles for drug metabolism in the small intestine of cynomolgus macaques as well as humans.
The rates of 7-ehoxyresorufin O-deethylation and bufuralol 1A-hydroxylation in the small intestine ( Table 1) were slower than those in the liver, which were reported previously. 9) Since cynomolgus CYP1A1 and CYP2D17 mainly catalyze 7-ehoxyresorufin O-deethylation and bufuralol 1A-hydroxylation, 1) respectively, the slower rates of these reactions might be partly accounted for by the lower expression of cynomolgus CYP1A1 and CYP2D17 in the small intestine than in the liver, as shown at the mRNA level. 7) Similarly, the rates of diclofenac 4A-hydroxylation and S-mephenytoin 4A-hydroxylation in the small intestine ( Table 1) were slower than those in the liver, which we reported previously.
9) The slower rates of these reactions might be partly accounted for by the lower expression of cynomolgus CYP2C19 and CYP2C9 in the small intestine than in the liver, as shown at the mRNA level, 7) due to the involvement of cynomolgus CYP2C19
and CYP2C9 in diclofenac 4A-hydroxylation and S-mephenytoin 4A-hydroxylation, respectively. 13) In contrast, the rate of paclitaxel 6¡-hydroxylation and testosterone 16¢-hydroxylation in the small intestine ( Table 1 ) was higher than that in the liver, which was reported previously. 9) Cynomolgus CYP2C8 and CYP2B6, responsible for paclitaxel 6¡-hydroxylation and testosterone 16¢-hydroxylation, respectively, 1, 13) are only minimally expressed in the small intestine, unlike in the liver, at the mRNA level.
7) The reasons for these high oxidation rates in the cynomolgus small intestine are not clear at present; however, several cynomolgus P450 forms might be involved in these reactions in the cynomolgus small intestine, presumably because cynomolgus P450 forms could have wide substrate specificity compared with human P450 forms. 14) In 40 MacfaCAM, all P450 metabolic activities varied to some extent (Supplemental Fig. 2) . The smallest variations were observed in bupropion hydroxylation (2.1-fold) ( Table 1) . The largest inter-animal variations were observed in bufuralol 1A-hydroxylation (82-fold), but the variations were 4.2-fold when the 3 poorest metabolizers were excluded (Table 1, Supplemental  Fig. 2) . Similarly, the inter-animal variation in diclofenac 4A-hydroxylation was 8.2-fold when the 2 poorest metabolizers were excluded. The inter-animal variation in 7-ethoxyresorufin Odeethylation was 9.3-fold when the 2 poorest metabolizers and the most extensive metabolizer were excluded (Supplemental Fig. 2 ). These inter-animal variations might partly account for the observation that P450 metabolic activities were not statistically significantly different among MacfaCAM, MacfaCHN, and MacfaIND.
Similarly, large inter-individual variations are observed in the metabolic activities and protein content of P450s in the human small intestine. 3, 15) In humans, intestinal CYP3A5 protein was not detected in 20 of 31 subjects, 3) at least partly due to genetic polymorphisms, including CYP3A5*3, that are prevalent extensively in human populations and associated with decreased expression levels of the protein in the liver and small intestine due to aberrant splicing caused by an intronic nucleotide change. 16) Similar defective alleles are found in cynomolgus CYP3A4 and CYP3A5. 17) Therefore, genetic polymorphisms might also affect inter-animal variations in P450 metabolic activities in cynomolgus macaques.
No statistically significant sex differences were found in the P450 metabolic activities of the 40 MacfaCAM animals analyzed ( Table 1) . The largest sex differences were observed in 7-ethoxyresorufin O-deethylation (1.2-fold) ( Table 1) . Similarly, qPCR analysis revealed no statistically significant differences between 10 males and 10 females of MacfaCAM in mRNA expressions of CYP1A1, CYP1D1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2C76, CYP2D17, CYP2E1, CYP3A4, or CYP3A5, which are involved in the metabolic activities measured in the present study (Supplemental Fig. 3) . The largest sex-biased expression was observed for CYP2E1 (4.4-fold), but the sex-biased expression of the remaining P450 mRNAs analyzed was <2.0-fold. Therefore, there were no statistically significant sex differences in P450 mRNA expression, possibly accounting for similar P450 metabolic activities in males and females. Similarly, no substantial sex differences in P450 content have been observed in the human small intestine.
3) Together with the major drug metabolism role of CYP3A, these results suggest that cynomolgus macaques might be an ideal animal species for drug metabolism studies.
Correlations between P450 mRNA expression levels were estimated to gain insight into the transcriptional mechanisms of cynomolgus P450s. PXR, one of the important regulators of P450 expression, was also included in the analysis. CYP3A4 mRNA was highly correlated (p < 0.05) with CYP2B6, CYP2C8, and CYP2C76 mRNAs, while CYP2C19 was highly correlated with CYP2B6 and CYP2C8 mRNAs ( Table 2) . CYP1A1, CYP2B6, and CYP2C8 mRNAs were highly correlated with each other. In contrast, there were no statistically significant correlations among CYP1D1, CYP2C9, CYP2D17, CYP2E1, CYP3A5, and PXR mRNAs ( Table 2) . These results suggest that some genes of the cynomolgus P450s relevant to drug metabolism might share the same transcriptional regulatory mechanisms in the small intestine.
Regulation of P450 gene expression is not understood well in the cynomolgus macaque. In humans, transcription factors such as PXR, constitutive androstane receptor, and peroxisome proliferator-activated receptor ¡ are important for regulation of P450 gene expression in the liver. These transcription factors are expressed at substantially lower levels in the small intestine, whereas hepatocyte nuclear factor 4¡ (HNF4¡), another important regulator of P450 expression, is expressed at similar levels in both tissues.
18) HNF4¡ Data represent the average « SD of 40 MacfaCAM (20 males, 20 females), 9 MacfaCHN (9 males), 5 MacfaIDN (4 males, 1 female). Drug-metabolizing enzyme activities were measured, as described in Materials and Methods, using P450 substrates (7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, S-mephenytoin, bufuralol, chlorzoxazone, and testosterone). All P450 metabolic activities were detected except for coumarin 7-hydroxylation and testosterone 16¡-hydroxylation.
a S-Mephenytoin 4A-hydroxylation was not detected in 4 samples (all MacfaCAM, 2 males and 2 females), and thus the data from 36 samples were used to calculate sex differences and inter-animal-variations, while the data from all 40 samples were used for the remaining reactions.
plays important roles in the regulation of CYP3A expression in the human small intestine. 18) Moreover, vitamin D receptor, expressed more abundantly in the small intestine than in the liver, 18) is also involved in the regulation of CYP3A expression in the human small intestine. 19) It is of great interest to investigate the involvement of HNF4¡ and vitamin D receptor for regulating P450 genes in the cynomolgus macaque small intestine.
In the present study, the results indicated no substantial differences among MacfaCAM, MacfaCHN, and MacfaIDN jejunum P450 metabolic activities (Table 1, Supplemental Fig. 1 ). Similar to the liver study, 9) this might be attributable to similar expression levels among MacfaCAM, MacfaCHN, and MacfaIDN, although mRNA expression was not measured for MacfaCHN or MacfaIDN due to the limited number of RNA samples available for qPCR analysis. MacfaCAM and MacfaCHN are especially genetically close, 9) partly supporting the similarities of jejunum P450 metabolic activities between MacfaCAM and MacfaCHN. Statistical significance was determined based on a p-value (probability that r is zero) of linear regression: *p < 0.05; **p < 0.01; ***p < 0.001. Expression of P450 mRNAs was measured in 20 MacfaCAM (10 males and 10 females) as described in Materials and Methods.
